1 hr ago
Crisil Raises Metropolis Healthcare’s Credit Outlook to Positive
Crisil Ratings gave Metropolis Healthcare a more positive outlook.
It kept the company’s long-term credit rating at AA-.
It also kept the short-term rating at A1+.
Crisil expects the company to grow faster and earn better profits.
Metropolis’s revenue increased by 24% in FY26.
Its acquired company, Core Diagnostics, may improve and help the business.
The company has much more net worth than debt, according to Crisil.
However, strong competition could still make business growth harder.
Crisil Ratings raised Metropolis Healthcare’s long-term outlook to “positive” from “stable” while reaffirming its “Crisil AA-” rating.
The agency retained the “Crisil A1+” rating on the company’s short-term bank facilities.
Crisil expects stronger organic growth, improved profitability and higher cash accruals, supported partly by a turnaround at Core Diagnostics.
Metropolis Healthcare’s revenue rose 24% to ₹1,646 crore in FY26, followed by 16.6% growth in the first quarter of FY27.
The company had ₹1,335 crore in adjusted net worth and about ₹232 crore in debt as of March 31, 2026, while competition remains a constraint.
- Who
- Crisil Ratings and Metropolis Healthcare Limited.
- What
- Crisil upgraded Metropolis Healthcare’s long-term rating outlook to “positive” from “stable” while maintaining its credit ratings.
- Where
- Mumbai; acquisitions have also expanded Metropolis Healthcare’s presence in north India.
- When
- The company reported FY26 results and first-quarter FY27 growth; its financial position was assessed as of March 31, 2026.
- Why
- Crisil expects stronger organic revenue growth, improved profitability, higher cash accruals and a potential turnaround at Core Diagnostics.
Key facts
- Long-term rating
- Crisil AA-, reaffirmed
- Long-term outlook
- Raised to positive from stable
- Short-term rating
- Crisil A1+, retained
- FY26 revenue
- ₹1,646 crore, up 24%
- First-quarter FY27 revenue growth
- 16.6%
- Adjusted net worth
- ₹1,335 crore as of March 31, 2026
- Total debt
- Approximately ₹232 crore as of March 31, 2026
Sources
Related news
Metropolis Healthcare targets technology-led growth amid local consolidation
Nomura Maintains Neutral Fortis Healthcare Rating Amid Growth Concerns
Park Medi World Plans 5,740-Bed North India Expansion Network
PL Capital Recommends Fortis Healthcare Shares, Sets ₹1,050 Target
Preventive Health Checks Gain Ground Across India’s Diagnostic Industry
JM Financial Sees 25-35% Upside in Three Buy Stocks
Insulin Resistance: A Growing Metabolic Health Crisis in India
